Home › Funds › Context Capital Management, LLC › TVTX

Context Capital Management, LLC position in TVTX

TRAVERE THERAPEUTICS INC · Health Care

Context Capital Management, LLC reported holding 62,700,000 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$73.1M, representing 2.43% of its reported portfolio and ranking #11 among its reported holdings. Context Capital Management, LLC has disclosed TVTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)62.70M sh
Reported value held$73.14M
Portfolio Weight2.43%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Context Capital Management, LLC's TVTX position evolved

Context Capital Management, LLC first disclosed a stake in TVTX in Q3 2023 at 41,167 shares (US$26.7M). The position peaked in Q3 2024 at 56,817 shares, worth US$49.09B. Across 13 filings, Context Capital Management, LLC increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 62,700,000 shares valued at US$73.1M — an increase of 12,200,000 shares quarter over quarter.. Notable position changes include a 129596% increase in Q4 2023 (shares fell 14% over the following quarter), a 479% increase in Q3 2025 (shares rose 60% over the following quarter), a 123853% increase in Q4 2025 (shares fell 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 41.17K $26.72M New
Q4 2023 53.39M $35.24B Add
Q1 2024 61.02K $39.03B Reduce
Q2 2024 60.74K $39.56B Hold
Q3 2024 56.82K $49.09B Reduce
Q4 2024 8.00K $7.86B Reduce
Q1 2025 8.00K $7.85B Hold
Q2 2025 8.00K $7.89M Hold
Q3 2025 46.35K $52.49M Add
Q4 2025 57.46M $81.99M Add
Q1 2026 52.93M $66.94M Reduce
Q2 2026 50.50M $59.46M Reduce
Q3 2026 62.70M $73.14M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TVTX and 13F data

TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 55 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Kynam Capital Management, LP (US$113.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TVTX

All TVTX fund holders →

FAQ

How long has Context Capital Management, LLC held TVTX?

Context Capital Management, LLC has disclosed TVTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Context Capital Management, LLC's current position in TVTX?

As of Q3 2026, Context Capital Management, LLC holds 62.70M shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $73.14M, representing 2.43% of its reported portfolio and ranking #11.

Has Context Capital Management, LLC been buying or selling TVTX?

In the latest 13F filing (Q3 2026), Context Capital Management, LLC increased its position in TVTX. The position peaked in Q3 2024 at 56.82K shares.

Which other funds hold TVTX?

Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 55 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.